Emorivir 200 mg Capsule
Emorivir 200 mg Capsule Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Emorivir 200 mg Capsule |
| Generic | Molnupiravir |
| Weight | 200 mg |
| Type | Capsule |
| Therapeutic Class | |
| Manufacturer | Beximco Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | September 24, 2024 at 5:38 am |
Uses
Emorivir 200 mg Capsule is an antiviral medicine used to treat mild to moderate C0VID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness. Emorivir 200 mg Capsule may help people with C0VID-19 stay out of the hospital and feel better. Emergency use authorized oral therapeutic for the treatment ... Read moreDosage
Emorivir 200 mg Capsule dosage
The recommended dose of Emorivir 200 mg Capsule is four 200 mg capsules (4+0+4), every 12 hours for 5 days. Do not give this medicine to children and adolescents aged less than 18 years. The use of Emorivir 200 mg Capsule in persons aged less than 18 years has not yet been studied.Side Effects
Common side effects include diarrhoea, nausea, feeling dizzy, headache.Precaution
There are limited clinical data available for Emorivir 200 mg Capsule. Serious and unexpected adverse events may occur that have not been previously reported with Emorivir 200 mg Capsule use.Interaction
No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with Emorivir 200 mg Capsule. Emorivir 200 mg Capsule is hydrolysed to n-hydroxycytidine (NHC) prior to reaching systemic circulation. Uptake of NHC and metabolism to NHC-TP are mediated by the same pathways involved in endogenous pyrimidine metabolism. NHC is not a substrate of major drug metabolising enzymes or transporters. Based on in vitro studies, neither molnupiravir nor NHC are inhibitors or inducers of major drug metabolising enzymes or inhibitors of major drug transporters. Therefore, the potential for molnupiravir or NHC to interact with concomitant medications is considered unlikely.Pregnancy & Breastfeeding use
Animal studies with molnupiravir have shown harmful effects to the unborn animal. Emorivir 200 mg Capsule is not recommended in pregnancy. Emorivir 200 mg Capsule has not been studied in pregnancy and it is not known if Emorivir 200 mg Capsule will harm your baby while you are pregnant. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice. If you can become pregnant, you should use effective birth control while you are taking Emorivir 200 mg Capsule and for 4 days after the last dose of Emorivir 200 mg Capsule. If you are breast-feeding or are planning to breastfeed, tell your doctor before taking this medicine. Breast-feeding is not recommended during treatment and for 4 days after the last dose of Emorivir 200 mg Capsule. This is because it is not known if Emorivir 200 mg Capsule gets into breast milk and will be passed to the baby.Contraindication
Emorivir 200 mg Capsule is contraindicated in patients with known hypersensitivity to Emorivir 200 mg Capsule.Storage Condition
Store at or below 25°C temperature. Keep away from light and wet places. Keep out of reach of children.Innovators Monograph
You find simplified version here Emorivir 200 mg Capsule
